Antifibrotic therapies: where are we now?

YJ Yoon, SL Friedman, YA Lee - Seminars in liver disease, 2016 - thieme-connect.com
Fibrosis is the wound-healing response of tissues to injury. Extensive characterization of
organ fibrosis mechanisms has identified common core pathways in renal, pulmonary, skin …

[HTML][HTML] SCARNA10, a nuclear-retained long non-coding RNA, promotes liver fibrosis and serves as a potential biomarker

K Zhang, Y Han, Z Hu, Z Zhang, S Shao, Q Yao… - Theranostics, 2019 - ncbi.nlm.nih.gov
Long non-coding RNAs (lncRNAs) are involved in numerous biological functions and
pathological processes. However, the clinical significance of lncRNAs and their functions in …

PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target

S She, X Wu, D Zheng, X Pei, J Ma, Y Sun, J Zhou… - Journal of …, 2020 - Elsevier
Background & Aims CC motif chemokine receptor 2 (CCR2) has been recognized as a
promising target for the treatment of liver fibrosis. PC3-secreted microprotein (PSMP) …

Collagenase-I decorated co-delivery micelles potentiate extracellular matrix degradation and hepatic stellate cell targeting for liver fibrosis therapy

L Zhou, Q Liang, Y Li, Y Cao, J Li, J Yang, J Liu, J Bi… - Acta Biomaterialia, 2022 - Elsevier
Liver fibrosis is a pathological process of multiple chronic liver diseases progressing to
cirrhosis for which there are currently no effective treatment options. During fibrosis …

[图书][B] Хронический вирусный гепатит С и цирроз печени

А Рахманова, А Яковлев, В Шаройко, В Кащенко - 2022 - books.google.com
В руководстве представлены результаты многолетнего труда авторов по проблемам
вирусных гепатитов, преимущественно прогрессирующих хронических и тяжелых форм …

[HTML][HTML] LOXL2—A new target in antifibrogenic therapy?

A Puente, JI Fortea, J Cabezas, MT Arias Loste… - International journal of …, 2019 - mdpi.com
The concept of liver fibrosis and cirrhosis being static and therefore irreversible is outdated.
Indeed, both human and animal studies have shown that fibrogenesis is a dynamic and …

SECs (sinusoidal endothelial cells), liver microenvironment, and fibrosis

V Natarajan, EN Harris… - BioMed research …, 2017 - Wiley Online Library
Liver fibrosis is a wound‐healing response to chronic liver injury such as
alcoholic/nonalcoholic fatty liver disease and viral hepatitis with no FDA‐approved …

[HTML][HTML] Inhibition of aquaporin-3 in macrophages by a monoclonal antibody as potential therapy for liver injury

M Hara-Chikuma, M Tanaka, AS Verkman… - Nature …, 2020 - nature.com
Abstract Aquaporin 3 (AQP3) is a transporter of water, glycerol and hydrogen peroxide
(H2O2) that is expressed in various epithelial cells and in macrophages. Here, we …

An update on the recent advances in antifibrotic therapy

F Tacke, R Weiskirchen - Expert Review of Gastroenterology & …, 2018 - Taylor & Francis
Introduction: Chronic injury to the liver, such as viral hepatitis, alcoholism, non-alcoholic fatty
liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), promotes extracellular matrix …

Food components with antifibrotic activity and implications in prevention of liver disease

M Bae, YK Park, JY Lee - The Journal of Nutritional Biochemistry, 2018 - Elsevier
Increasing prevalence of nonalcoholic fatty liver disease (NAFLD) in parallel with the obesity
epidemic has been a major public health concern. NAFLD is the most common chronic liver …